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Objective: Endovascular abdominal (EVAR) and thoracic (TEVAR) endografts allow aneurysm repair in high-risk
patients, but infectious complications may be devastating. We reviewed treatment and outcomes in patients with infec-
ted aortic endografts.
Methods: Twenty-four patients were treated between January 1997 and July 2012. End points were mortality, morbidity,
graft-related complications, or reinfection.
Results: Twenty males and four females with median age of 70 years (range, 35-80 years) had 21 infected EVARs and 3
TEVARs. Index repairs performed at our institution included eight EVARs and two TEVARs (10/1300; 0.77%). There
were 19 primary endograft infections, 4 graft-enteric ﬁstulae, and 1 aortobronchial ﬁstula. Median time from repair to
presentation was 11 months (range, 1-102 months); symptoms were fever in 17, abdominal pain in 11, and psoas abscess
in 3. An organism was identiﬁed in 19 patients (8 mono- and 11 polymicrobial); most commonly Staphylococcus in 12 and
Streptococcus in 6. All but one patient had successful endograft explantation. Abdominal aortic reconstruction was in situ
repair in 21 (15 rifampin-soaked, 2 femoral vein, and 4 cryopreserved) and axillobifemoral bypass in three critically ill
patients. Infected TEVARs were treated with rifampin-soaked grafts using hypothermic circulatory arrest. Early mortality
(30 days or in-hospital) was 4% (n [ 1). Morbidity occurred in 16 (67%) patients (10 renal, 5 wound-related, 3
pulmonary, and 1 had a cardiac event). Median hospital stay was 14 days (range, 6-78 days). One patient treated with in
situ rifampin-soaked graft had a reinfection with fatal anastomotic blowout on day 44. At 14 months median follow-up
(range, 1-82 months), patient survival, graft-related complications, and reinfection rates were 79%, 13%, and 4%,
respectively.
Conclusions: Endograft explantation and in situ reconstruction to treat infections can be performed safely. Extra-anatomic
bypass may be used in high-risk patients. Resection of all infected aortic wall is recommended to prevent anastomotic
breakdown. Despite high early morbidity, the risk of long-term graft-related complications and reinfections is low. (J




Coronary artery disease 67
Peripheral vascular disease 28
Chronic renal insufﬁciency 28
Diabetes 6
Tobacco use 94
Immunosuppressive 11The endovascular approach to aortic aneurysm repair
was initially developed as an alternative to open repair in
the otherwise medically unﬁt or poor surgical candidates.
However, over time, this has become the preferred
approach with lower perioperative morbidity, mortality,
and shorter hospital stay, with outcomes comparable to
that of open approach.1,2 Unfortunately, complications of
abdominal endovascular aneurysm repair (EVAR) and
thoracic endovascular aneurysm repair (TEVAR) may re-
quire treatment that is more complex and high risk than
if the original procedure was done with an open technique,
such as the management of the infected endograft.
Infection of prosthetic endograft is rare but is a devas-
tating complication associated with high mortality. This
makes it imperative that it be recognized early with aggres-
sive workup and optimal treatment to improve outcome.the Division of Vascular and Endovascular Surgery, Mayo Clinic.
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://dx.doi.org/10.1016/j.jvs.2013.01.047The incidence of infected abdominal and thoracic aortic
endografts varies from 0.2% to 5% based on case reports
and small case series.3-9 The current series is aimed at
providing a diagnostic and treatment algorithm based on
our experience with infectious complications after abdom-
inal and thoracic endovascular aortic aneurysm repairs.METHODS
After approval from the Institutional Review Board,
the surgical index and database were queried to identify
all consecutive patients who underwent endovascular
repair of aortic aneurysms at the Mayo Clinic between
January 1997 and July 2012. The search was broadened
to ﬁnd all patients with the diagnosis of infected endograft
at the Mayo Clinic in order to capture all cases, whether371










1 74 M 151 EVAR Fever CT, WBC scan
2 74 M 1856 EVAR Fever, ruptured aneurysm CT
3 68 M 71 EVAR Fever, night sweats, urosepsis CT, WBC scan
4 63 M 525 EVAR Fever, night sweats, weight loss CT, WBC scan
5 70 M 60 EVAR Fever, abdominal pain, groin abscess CT, WBC scan
6c 68 F 693 EVAR Abdominal pain CT, WBC scan
7 71 M 88 TEVAR Fever, night sweats CT
8 67 M 662 EVAR Abdominal pain CT, WB scan
9c 68 F 254 EVAR Fever, contained rupture CT
10 70 M 482 EVAR Psoas abscess, abdominal pain CT, WBC scan
11 74 M 2451 EVAR Fever, abdominal pain, night sweats, urosepsis CT, WBC scan
12 71 M 156 EVAR Fever, abdominal pain, groin abscess CT
13 60 M 608 EVAR Psoas abscess, abdominal pain CT, WBC scan
14 78 M 3045 EVAR Fever CT, WBC scan
15 35 F 33 TEVAR Fever, hempotysis aortobronchial ﬁstula CT, WBC scan
16 62 M 150 EVAR Fever, discitis, bacteremia CT, WBC scan
17 61 F 44 EVAR Abdominal pain, muscle spasms CT
18 79 M 797 EVAR Urosepsis CT
19c 74 M 2815 TEVAR Abdominal pain, ﬂu-like symptoms CT, WBC scan
20 62 M 365 EVAR Fever CT, WBC scan
21 64 M 244 EVAR Fever, abdominal pain CT
22c 73 M 308 EVAR Psoas abscess, fever, night sweats CT, WBC scan
23c 80 M 1689 EVAR Fever, abdominal pain CT, WBC scan
24 72 M 137 EVAR Fever, GI bleed, sepsis CT
ARF, Acute renal failure; CT, computed tomography; DVT, deep vein thrombosis; EVAR, endovascular aneurysm repair; GI, gastrointestinal; GPC, gram-
positive coccal; MI, myocardial infarction; MRSA, methicillin-resistant Staphylococcus aureus; TEVAR, thoracic endovascular aneurysm repair; WBC, white
blood cell.
aAll but one patient had been on antibiotics prior to presentation.
bPartial graft excision for limited infection.
cWhile the cultures remained negative in these patients, the preoperative radiographic and intraoperative ﬁndings were diagnostic for endograft infection.
dCryopreserved.
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outside facility. Infection of aortic endograft was deﬁned
as radiographic ﬁnding of perigraft ﬂuid or abscess, clinical
presentation of the patient, positive blood or aortic wall
cultures, and intraoperative ﬁndings of infection, puru-
lence, or inﬂammation. Aortoenteric graft erosion or
ﬁstula was deﬁned as loss of fat plane between bowel
and aortic wall, herald bleed followed by visual conﬁrma-
tion on endoscopy, and intraoperative ﬁnding of aorto-
enteric communication with evidence of enteric staining
of the endograft prosthesis on explantation. Data acquisi-
tion was performed in a retrospective fashion from patient
medical records including their preoperative cardiovascular
risk factors, clinical signs and symptoms at presentation,
and perioperative management. End points includedsurvival, early and late postoperative complications
including reinfection, and graft-related complications
such as limb occlusion or aneurysm recurrence. The early
perioperative period was deﬁned as duration of the index
hospitalization regardless of the number of days or within
30 days of the operation. This information was then used
to determine a preferred treatment strategy for patients
with infected endovascular grafts.
Statistics. All categorical data are expressed as mean 6
standard error of the mean or median (with range) as
appropriate.
RESULTS
Twenty-four patients, with 21 abdominal aortic and
three thoracic stent grafts, were treated at the Mayo Clinic
Microbiologya
Procedure performed Early outcome Late outcomeBlood culture Aortic wall culture
Streptococcus Enterobacter, Staph, Strep In situ reconstruction Lymph leak
Gemella morbillorum,
Fusobacterium
In situ reconstruction Seroma
Staph aureus In situ reconstruction ARF
Staph aureus In situ reconstruction





In situ reconstruction ARF





Streptococcus Streptococcus In situ reconstruction ARF
DVT
Staph aureus Staph aureus In situ reconstruction ARF






Axillobifemoral graft Prolonged vent support
Prevotella, Strep viridans In situ reconstruction ARF, groin hematoma,
prolonged vent support
MRSA MRSA In situ reconstruction Reinfection þ proximal
anastomotic blowout
Staph aureus In situ reconstructionb Chyle leak
Salmonella Pseudomonas In situ reconstructiond ARF, Aﬁb








In situ reconstructiond ARF
In situ reconstruction
In situ reconstruction ARF, MI
Prevotella, GPC In situ reconstructiond ARF, hemothorax,
pneumonia
Table II. Continued.
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2012. During this 15-year period, 1300 patients under-
went endovascular aortic stent placement; of these, 1098
were abdominal (EVAR) and 202 were thoracic (TEVAR)
endografts. The incidence of infection in patients with
index endovascular graft placement at Mayo Clinic for
EVARs was 8 of 1098 (0.7%) and 2 of 202 TEVARs (1%).
Patient demographics. Twenty males (79%) and four
females with a median age of 70 years (range, 35-80 years)
met the inclusion criteria for this cohort. Their comorbid-
ities are depicted in Table I. Twenty of the 24 patients
(83%) had at least one alleged risk factor for seeding
infection, including one or more secondary endovascular
reinterventions (8), aortoduodenal ﬁstulae (4), recurrent
urosepsis (3), recurrent episodes of pneumonia (2), colonresection for ischemic colitis (1), appendectomy (1), groin
infection (1), epidural abscess (1), or recent history of
tooth extraction (1). Indication for index endovascular
aortic repair was aneurysmal disease in 22 patients and
pseudoaneurysm following a prior open aortobifemoral
repair for occlusive disease in two patients using an AneuRx
(Medtronic, Minneapolis, Minn) in one patient and a Gore
Excluder (Gore, Flagstaff, Ariz) device in the other. The
AneuRx graft was retrieved from seven patients, Gore
Excluder devices from eight patients, Zenith (Cook,
Bloomington, Ind) in four patients, and Ancure (Endo-
vascular Technologies, Menlo Park, Calif), Bolton (Bolton
Medical, Sunrise, Fla), and PowerLink by Endologix
(Irvine, Calif) were found in one each. The remaining two
graft devices were not identiﬁed.
Fig 1. Computed tomography (CT) scan reveals periaortic ﬂuid
with gas bubbles (white arrow) and psoas abscess (double arrow)
suggestive of infected aortic aneurysm.
Fig 2. A focus of intense radiotracer uptake is present immediately
anterior to the bifurcated aortoiliac graft interposed between the
prior aneurysm sac and the transverse duodenum.
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time of presentation. The most common symptom was
fever and weight loss associated with malaise and signs
of systemic illness, abdominal pain, aortoenteric ﬁstulae
suspected on preoperative computed tomography (CT)
imaging, psoas or groin abscess, and aneurysm rupture
(Table II). Median time from start of symptoms to
presentation was 17 months (range, 1-102 months).
Diagnostics. One patient was taken to the operating
room directly from the emergency room without any
preoperative evaluation other than an outside CT with
evidence of ruptured aneurysm. The remaining 23 patients
underwent extensive workup, including diagnostic tests,
preoperative cultures, and/or percutaneous abscess
drainage with initiation of antibiotics prior to aortic
debridement. When endograft infection is suspected, our
institutional algorithm includes computed tomography
angiogram (CTA), white blood cell scan, blood cultures
prior to initiation of antibiotics when possible, and upper
endoscopy in patients presenting with upper gastrointes-
tinal bleed or melena. CTA (Fig 1) at initial presentation
demonstrated perigraft ﬂuid collection in 19 patients;
periaortic abscess was deﬁned by the presence of air in
perigraft ﬂuid in 13 patients. A tagged white blood cell scan
(Fig 2) was performed in 16 patients; 15 of these were
positive with focus of intense radiotracer uptake. One
patient was diagnosed with aortoenteric ﬁstula preopera-
tively on upper gastrointestinal endoscopy. Nineteen
patients had leukocytosis on initial presentation. During
the extensive workup for suspected endograft infection, the
CTA of one patient (patient #9 in Table II) was concerning
for possible rupture, with resultant expeditious operative
intervention.
Microbiology. Blood cultures were drawn in all
except two patients who had been on prolonged anti-
biotic therapy prior to presentation. Nine of these patients
had positive blood cultures preoperatively. Aortic wall
cultures sent intraoperatively were positive in 19 patients.
Of these, eight were monomicrobial, and 11 were polymi-
crobial. The most commonly identiﬁed organism was
Staphylococcus aureus in 12 patients; at least two were
methicillin-resistant Staphylococcus aureus (MRSA). Other
organisms included Streptococcus, Pseudomonas, Prevotella,
and Salmonella baildon (non-typhi). Four patients had
positive fungal cultures (Table II). All except one patient
had been initiated on broad-spectrum antibiotics prior to
being taken to the operating room.
Operative approach. Explantation of infected aortic
endograft was performed in all 24 patients, one emer-
gently and 23 after completion of preoperative workup.
All but three patients underwent excision of the entire
infected graft; in three patients, the infection was limited
to the limb extending proximally from the infected groin,
and therefore, excision of the infected limb was under-
taken to healthy-appearing tissue, which was then con-
ﬁrmed by negative margin on intraoperative pathology.
Four patients had aortoenteric ﬁstula requiring endograft
explantation and bowel resection or repair (Fig 3,A and B).If abscess or frank purulence was noted intraoperatively
(Fig 4), autogenous vein graft or cryopreserved graft was
preferred. In situ reconstruction, our preferred approach
in patients without abscess or frank purulence, was
performed in 21 patients, including all three thoracic
aortic repairs.10 In situ rifampin-soaked Dacron grafts
were utilized in 15 patients, superﬁcial femoral vein graft
in two patients, and cryopreserved graft (CryoLife, Inc,
Kennesaw, Ga) in four patients (Fig 5). Rifampin-soaked
grafts were prepared by soaking a Dacron graft in 60 mg/
mL rifampin solution for 30 to 60 minutes. Cryopreserved
grafts were stored at 180C to 196C and thawed
to 37C to 42C prior to use. Three patients deemed high
risk for an extensive in situ single-stage operation were
Fig 3. A, Intraoperative ﬁndings demonstrating aortoduodenal ﬁstula (arrow). B, Explanted graft with bile staining
(arrow).
Fig 4. Intraoperative picture of frank perigraft purulence.
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lowed by explantation 48 hours later. One of these patients
indeed had a signiﬁcant amount of purulence and therefore
was left with an aortic stump wrapped in a 360-degree
omental ﬂap. In the other two patients, we used a staged
technique of placing an axillobifemoral graft ﬁrst, which is
a shorter and clean procedure in these high-risk patients. By
staging the procedure, we have found that we are able to get
very high-risk patients through with lower mortality. At the
next procedure, we plan to place an in situ graft, but we have
the alternative of oversewing the aorta since the axillobife-
moral graft is already in place in a clean ﬁeld. If the patient
becomes unstable, the aorta can be oversewn, and the lower
limbs remain perfused.
All patients with thoracic aortic infection required
establishment of hypothermic circulatory arrest to accom-
plish infected graft explantation and in situ reconstruction.One of the patients with an infected thoracic endograft
had previously been treated with open repair for aortic
coarctation complicated by an aortobronchial ﬁstula for
which she underwent endograft placement. At the time
of transfer to our facility 33 days postoperatively, she was
critically ill, septic, and on heavy pressor support. Extra-
anatomic ascending aorta to descending thoracic aortic
bypass with rifampin-soaked Dacron grafts was performed
with endograft explantation, followed by extracorporeal
membrane oxygenation for respiratory support. A pedicle
of diaphragm was wrapped around the anastomosis, and
the aortic stump was buttressed with bovine pericardium.
The postoperative course was complicated with bleeding,
acute renal failure, and respiratory failure requiring trache-
ostomy. After a prolonged hospital stay of 64 days, the
patient was discharged with no sequelae at 6-month
follow-up. One patient with a history of prior open type
III thoracoabdominal aortic aneurysm repair followed
by multiple thoracic stent grafts developed persistent
infection for which he underwent endograft explantation
with rifampin-soaked grafts. Despite successful technical
repair, the patient failed resuscitation after cardiopulmo-
nary arrest.
Three patients had focal infection of one limb of the
bifurcated aortic stent, associated with groin abscesses.
These patients had focal areas of infection based on CTA
and white blood cell scan, as well as intraoperative appear-
ance and conﬁrmation by pathology. We often send intra-
operative histology to look at frozen section for white
blood cells and bacteria in the aortic wall to conﬁrm
whether more artery should be removed. Given the above
evidence of localized infection and baseline poor clinical
status of the patients, the decision was made to not explant
Fig 5. After explantation of infected endograft, in situ reconstruction is the preferred repair using three different graft
materials as indicated: rifampin-soaked Dacron, autogenous vein, or cryopreserved graft.
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much greater morbidity. These patients were maintained
on life-long suppressive antibiotics and have done well
with no evidence of residual infection.
Partial graft excision was performed with complete
eradication of infected tissue and preservation of healthy
uninfected aortoiliac graft. Local primary in situ recon-
struction was performed in two patients. In the third
patient, axillounifemoral bypass was performed using
rifampin-soaked Dacron grafts (proximal two-thirds) and
reversed femoral vein grafts in the distal one-third due to
excessive groin purulence. All in situ reconstructions were
protected with autogenous 360 tissue coverage using
omental ﬂaps when available (14 patients; Fig 6); rectus
femoris muscle ﬂap and fascia lata were used in the
remainder. Aortic sac was closed over the reconstruction
in one patient due to the lack of omental tissue. Serratus
anterior and diaphragm pedicle wrap were used for
coverage in the two patients with thoracic repairs.
Postoperative antibiotics. Antibiotic treatment was
continued for life in 14 of the 23 patients alive (61%).
These patients either had more virulent microorganisms
on culture, prosthetic graft as conduit, or partial excision
of the endograft (infected segment was removed). Antibi-
otics were continued for a period of 6 weeks based on
cultures and susceptibilities in patients with autogenous
tissue, minimal risk factors for reinfection, and less virulent
microorganisms on culture. None of these patients had any
evidence of reinfection or developed resistance or allergies
to antibiotics at the time of last follow-up.OUTCOMES
Overall survival. There was one early (in-hospital or
30-day) mortality; four others died at 2, 3, 10, and
66 months. Overall survival was 79% at last follow-up
(Table III). One patient died intraoperatively, and one due
to graft reinfection with anastomotic blowout on post-
operative day 44. The cause of death in the remaining three
patients was not attributable to graft-related complications
or reinfection. Median length of hospital stay was 14 days
(range, 6-78 days). Median follow-up for this cohort was 14
months (range, 1-82 months). These patients are followed
up 4 to 6 weeks postoperatively to assess early complications
and reassess antibiotic needs, then at 3 to 6 months after
operation with a CT scan. If they remain stable, they are
followed annually to ensure late complications are diag-
nosed and addressed. While no patients were lost to follow-
up, 8 of these 24 patients were treated within the last year.
Early. One patient died intraoperatively. Postoperative
complications occurred in 17 patients (71%) including
acute renal failure, deep vein thrombosis, hematoma
treated with operative exploration and evacuation, seroma,
and lymph leak (Table II).
Late. Major complications occurred in four patients
(17%) including the patient with anastomotic blowout
due to reinfection. One patient developed acute symptom-
atic occlusion of the axillobifemoral bypass 1 year postop-
eratively and was treated with thrombolytic therapy with
excellent results. Two patients developed aneurysm recur-
rence at the proximal anastomotic site; one was repaired
with an endovascular stent placement, while the other
Fig 6. Technique for explantation of infected aortic endograft and replacement with in situ rifampin-soaked Dacron
grafts. A, In situ endograft preoperatively. B, Proximal and distal controls are established and the infected endograft
is removed with debridement of all infected tissue. C, Rifampin-soaked Dacron graft is used to replace the endograft.
D, A tongue of omentum is brought retrocolic, and a 360 omentum wrap is performed.
Table III. Outcome in patients with infected aortic
endografts after explantation
Overall survival, No. (%) 19/24 (79)
Early (30-day) mortality, No. (%) 1/124 (4)
Early morbidity, No. (%) 17/24 (71)
Graft-related complications, No. (%) 4/24 (17)
Reinfection, No. (%) 1/24 (4)
Median hospital stay, days (range) 14 (6-78)
Median follow up, months (range) 14 (1-82)
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complications was 87% at median follow-up of 14 months
(range, 1-82 months).
DISCUSSION
With advancements in endograft technology, and
improvement in device design and delivery mechanisms,
the endovascular approach has become a widely acceptedand most commonly utilized approach for aortic aneu-
rysm repair. While only a small fraction of patients under-
going endovascular repair for aortic aneurysms are faced
with the challenging problem of endograft infection, the
absolute increase in numbers raises the concern regarding
the ideal treatment strategy for this subset of patients.
Literature on open aortic infections reports an incidence
of 0.2% to 3%.10 Numan et al and Setacci et al have
compiled data from case reports and case series in pub-
lished literature from multiple institutions in order to
review preoperative workup, different treatment options
undertaken, and their outcomes.11,12 Our experience
with this largest single-center cohort is similar to those
quoted in these reviews. This study shows that the infec-
tion rate in patients undergoing endovascular aortic aneu-
rysm repair is comparable to that of open aortic repairs
(0.6%). Other authors have reported a similar incidence
of <1% for abdominal aortic graft infections and as
high as 5% for thoracic aortic graft infections.3,4,6-8
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repairs at our institution; we hypothesize it occurs
secondary to stent migration, severe angulations causing
repetitive frictional wear/tear, and possibly also due to
ﬁxation hooks resulting in endograft erosion through
the aortic wall into the duodenum. The clinical presenta-
tion of infected endografts is similar to that of infection
after open repair with non-speciﬁc signs such as fever,
weight loss, malaise, and abdominal pain. Also similar
was the extensive workup including blood cultures,
CTA, and tagged white blood cell scan followed by
cardiopulmonary workup to determine the best operative
approach. The presence of positive cultures, perigraft ﬂuid
with the presence of air therein, or associated psoas or
groin abscess was indicative of an infected endograft.
Two patients in our series while in the process of being
worked up for suspected infection presented with con-
tained rupture.
Twenty of the 24 patients were found to have historical
characteristics that may have been risk factors for infection.
Vogel et al identiﬁed the presence of perioperative septi-
cemia as a risk factor for graft infection in the study.13
Eight patients had at least one invasive secondary interven-
tion related to an endoleak. Three patients had multiply
recurrent urinary tract infections, and two patients had
pneumonia during the period from index repair to presen-
tation with an infected endograft. One patient had a recent
history of a dental procedure. While there is no evidence
that secondary interventions, perioperative infection, and
sepsis are risk factors, it may be that these patients are
susceptible to endograft infections.
Our management of patients with infected aortic
endografts is based on lessons learned and results from
our open aortic graft infections, and we have experienced
low reinfection rates (4%; n ¼ 1) and graft-related mor-
bidity (13%) with infected endograft patients.14-17 While
axillobifemoral bypass graft once was considered the only
viable option for treatment of infected aortic grafts, we
have shied away from them secondary to the associated
high risk of aortic stump disruptions (20%), amputation
rate of 20% to 29%, and a reinfection risk of up to
20%.11,15,17,18 Also, this may not be a feasible approach
for patients with para-visceral or thoracoabdominal aneu-
rysms, in patients with suprarenal ﬁxation, or those with
poor quality of tissues. In our experience, mortality associ-
ated with in situ reconstruction for infected open aortic
grafts was 8% with 100% limb salvage.16,19 All our
aortoenteric ﬁstulae in the open series (n¼ 54) were treated
with in situ repair with a mortality rate of 2.3% and
a reinfection rate of 4%.19 Rifampin-soaked polyester
grafts wrapped 360 in autogenous tissue (preferably
omentum) was the conduit of choice in our open as well
as endograft infections.4,19
In patients bacteremic with virulent micro-organisms or
when frank purulence or a large abscess was encountered
intraoperatively, we opted to use autologous vein graft,
and more recently, have preferred to use cryopreserved
graft (4 of 24 patients), as it obviates the prolongedoperative time required for deep vein harvesting, especially
in urgent situations or in patients with high cardio-
pulmonary risk who cannot tolerate prolonged anesthesia.20
Cryopreserved arterial grafts have been shown to be more
resistant to reinfection and promising outcomes with lower
mortalities of 5% to 9%, 100% limb salvage, and 2% aneu-
rysmal degeneration, as also noted by Setacci et al.11,21-25
However, we acknowledge that cryopreserved allografts
are signiﬁcantly more expensive than antibiotic-soaked
prosthetic grafts. Use of spiral vein reconstruction is another
option that has recently been described by Van Zitteren et al
and involves harvesting greater saphenous vein, which is
then cut open longitudinally and tightly placed on a
15-mm-diameter tube to construct a suitably ﬁtting graft,
using continuous sutures (Vascuﬁl 6/0) with 1-mm inter-
vals. This is then used for in situ aortic reconstruction.26
Nonexcisional therapy for treatment of infected aortic
endografts has met with high mortality rates ranging
from 33% to 70%.3-5,11,27 At our institution, we have
not managed any infected endografts nonoperatively. We
advocate removal of all infected material followed by
reconstruction and antibiotic suppressive therapy. In
high-risk patients, we have opted for staged extraanatomic
revascularization ﬁrst to reduce cardiac afterload and allow
shorter, albeit two or more, procedures.
All patients at our institution were initiated on antibi-
otic therapy as soon as endograft infection was suspected
and cultures were drawn. Patients remained on therapy
during the period of workup, perioperatively, and were
continued for a 4- to 6-week period intravenously. If
virulent organisms were encountered, abscess or frank
purulence was noted intraoperatively, or if partial excision
of graft was undertaken, oral antibiotics were continued as
life-long suppressive therapy. Patients with autogenous
venous conduit and favorable risk factors and those with
negative blood and aortic wall cultures were treated
with a ﬁnite period of antibiotic therapy. Neither group
of patients had any evidence of reinfection at a median
follow-up of 14 months. There is currently no consensus
or data that recommend an appropriate duration of anti-
biotics in this group of complex patients, and therefore,
it is largely determined by patient presentation, degree
of purulence noted intraoperatively, choice of conduit
(autogenous vs prosthetic), patient risk factors for reinfec-
tion, and virulence of cultured organisms.28,29
CONCLUSIONS
Based on our experience in these 24 patients, infected
aortic abdominal and thoracic endografts can be treated
safely and effectively by device explantation with in situ
reconstruction. While rifampin-soaked Dacron graft is our
preferred choice in most cases, when faced with infection
with virulent organisms or frank purulence such as an
abscess, autologous grafts (vein or cryopreserved) may be
a better choice. Extra-anatomic reconstruction may be
considered in high-risk patients. Perioperative complica-
tions occurred frequently, and graft-related late complica-
tions occurred in 12.5% of our patients. Endograft
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Fatima et al 379explantation with suppressive antibiotics appears to be asso-
ciated with a low risk of reinfection.
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